Ionis Pharmaceuticals Inc Q2 2021 Earnings Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Two quick questions on tofersen. What read across to the rest of your neuro pipeline do you think investors can and cannot make based on the upcoming Phase III results? And second one related to that product. Can you talk about the reason why the compassionate use is currently restricted to those patients with the most rapidly progressing disease?

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : Just a quick question on the MAPT data at ARC. I noticed that particularly on the total tau levels, they seem to keep decreasing even though these patients have been off 4 months of drug -- or been off drug for 4 months. So I'm just wondering how you're thinking or how large you may be thinking about dosing frequency in that particular indication as you move into a better powered Phase II? And in the publication, will that include city or some of the boxes followed up for this long-term extension part?

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : And then just with the city on some of the boxes, is that something that will be included in the publication? Or was that only measured as baseline to screen these patients in?